Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Online Videos | News | Weblinks | Medicines | Poem/Story | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Tricyclic and Related Antidepressants

Uses
  • Depression - moderate to severe forms; especially depression associated with physiological or psychomotor changes
  • Panic disorder
  • Anxiety disorders - general anxiety disorder, mixed anxiety-depression, phobic disorders
  • Post-traumatic stress disorder
  • Obsessive-compulsive disorder
  • Other possible uses - neuralgia, nocturnal enuresis, chronic fatigue syndrome
Types
  • Tricyclic antidepressants
    • Sedating: useful in agitated and anxious depressed patients. Include amitriptyline, clomipramine, dosulepin (dothiepin), doxepin, and trimipramine.
    • Less sedating: useful in withdrawn patients. Includes amoxapine, imipramine, lofepramine, nortriptyline.
  • Related antidepressants: have a similar structure to tricyclic antidepressants and consist of maprotiline, mianserin and trazodone.
Points to consider before starting1
  • Lower doses in elderly patients
  • Convenient as long acting therefore, can give once daily
  • Imipramine and amitriptyline - marked antimuscarinic and cardiac side-effects
  • Doxepin, trazodone and mianserin - less antimuscarinic and more cardiotoxic
  • Lofepramine has lower incidence of antimuscarinic side effects and sedation but associated with hepatic toxicity.
  • Amoxapine is associated with tardive dyskinesias.

Relative presence of adverse effects of various tricyclic antidepressants

 
Sedation
Cardiotoxicity
Antimuscurinic
activity
Amitriptyline
+++
+
+++
Imipramine
++
+
+++
Clomipramine
+++
 
+++
Dosulepin
+++
 
+++
Doxepin
+++
+++
++
Trimipramine
+++
 
+++
Lofepramine
+
 
+
Nortriptyline
++
 
+++
Trazodone
+++
+++
++
Mianserin
+++
+++
++

If there are concerns regarding side-effects or the patient may be more prone to adverse effects then it may be prudent to start at 50% of the dose and monitor for side effects and titrate up.

Contraindications
  • Arrhythmias
  • Recent myocardial infarction
  • Liver disease
  • Glaucoma
  • Mania.
Monitoring a patient on TCAs2
  1. Inform patients about side effects especially drowsiness and dangers of suddenly stopping.
  2. Check pulse rate, BP, ECG.
  3. Monitor liver function tests if patient on lofepramine e.g. every two weeks for the first month and then every month for the first three months then six monthly.3
  4. When discontinuing ensure gradual dose reduction and monitoring for relapse (some patients develop symptoms although, not strictly addictive).
Side-effects
  1. Cardiotoxicity - arrhythmias and heart block especially with amitriptyline
  2. Antimuscarinic effects e.g. drowsiness, dry mouth, blurred vision and constipation. Some tolerance occurs.
  3. Convulsions
  4. Hypotension - especially in elderly
  5. Hyponatraemia - may lead to confusion in the elderly
  6. Hepatic dysfunction
  7. Haematological abnormalities e.g. leucopenia, thrombocytopenia and agranulocytosis.
TCA and overdose2

TCAs are most toxic of all the antidepressants, particularly amitriptyline and dothiepin, especially when taken in overdose.4 1 in 40 TCA ODs will die - an ingestion of 35mg / kg is the median lethal dose for an adult.

Presentation

  • Agitation
  • Lethargy
  • Hyper / hypothermia and metabolic acidosis
  • Anticholinergic effects - muscle twitching, dilated pupils, urinary retention, GIT problems
  • Seizures - occurs in up to 20% of patients and associated with severe toxicity, hypoxia and metabolic acidosis.
  • Arrhythmias - commonest cause of death. Sinus tachycardia is seen as is prolongation of the QRS complex which predisposes to Torsades de Point which can be fatal.
  • Disorientation, confusion, hallucinations and eventual coma
  • Cerebellar signs - nystagmus, dysarthria, ataxia
  • Other neurological deficits e.g. hyperreflexia, upgoing plantars.

Serious complications tend to occur within 12h of ingestion. Gastric decontamination OK for up to about 8h post ingestion.

Treatment

  • Refer urgently to nearest Accident and Emergency department
  • Supportive measures e.g. resuscitation, high flow oxygen, cardiac monitor, intravenous cannula and fluids if needed. Control of seizures with benzodiazepines.
  • Serial ECGs are required initially e.g. every 15- 20 minutes.
  • Arterial blood gases will give information regarding acidosis.
  • Activated charcoal - only effective for the first 8 hours after ingestion.
  • No antidote is available.
  • Patients should be admitted to HDU or ITU for high intensity observation.
  • If arrhythmias occur avoid common anti-arrhythmics e.g. beta blockers, calcium channel blockers as these can make the ECG difficult to interpret and some may interact with the TCA leading to worsening of cardiotoxicity.
  • Sodium bicarbonate is also used if needed - usually in severe cases of toxicity with either ECG changes such as broad QT interval or severe metabolic acidosis. Toxbase5 or the local poisons unit should be contacted for advice.
Other uses of antidepressant medication
  • Insomnia e.g. sedating TCA - amitriptyline and trazodone. Usually in low doses. Evidence suggests useful in depression related insomnia but data on use in insomnia alone is lacking.6
  • Anxiety e.g. TCA's like buspirone have been used.
  • Pain relief - TCA's, SSRI's and novel antidepressants have been used e.g. venlafaxine. TCA's have been found to be efficacious in the treatment of neuropathic pain in meta-analyses. In some trials SSRIs are less effective.7
  • Obsessive-compulsive disorder - clomipramine is used.
  • Fibromyalgia - TCA's are mildly effective.
  • Headaches - a recent meta-analysis revealed that SSRIs are not more useful than placebo in migraines and are less efficacious than TCA's in chronic tension headaches.8


Document references
  1. British National Formulary British Medical Association and Royal Pharmaceutical Society of Great Britain. London.
  2. Moulton and Yates; Lecture Notes in Emergency Medicine; 2006.
  3. Kelly C, Roche S, Naguib M, et al; A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int Clin Psychopharmacol. 1993 Summer;8(2):83-6. [abstract]
  4. Cheeta S, Schifano F, Oyefeso A, et al; Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry. 2004 Jan;184:41-7. [abstract]
  5. Toxbase; National Poisons Information Service
  6. No authors listed; Insomnia: assessment and management in primary care. National Heart, Lung, and Blood Institute Working Group on Insomnia. Am Fam Physician. 1999 Jun;59(11):3029-38. [abstract]
  7. Maizels M, McCarberg B; Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005 Feb 1;71(3):483-90. [abstract]
  8. Moja PL, Cusi C, Sterzi RR, et al; Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002919. [abstract]

Internet and further reading AcknowledgementsEMIS is grateful to Dr Gurvinder Rull for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 437
Document Version: 1
DocRef: bgp25018
Last Updated: 2 Oct 2007
Review Date: 1 Oct 2008






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page